EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY 4.0

Effect of Methylfolate, Pyridoxal-5′-Phosphate, and Methylcobalamin (SolowaysTM) Supplementation on Homocysteine and Low-Density Lipoprotein Cholesterol Levels in Patients with Methylenetetrahydrofolate Reductase, Methionine Synthase, and Methionine Synthase Reductase Polymorphisms: A Randomized Controlled Trial

Evgeny Pokushalov iD, Andrey Ponomarenko iD, Sevda Bayramova, Claire Garcia, Inessa Pak, Evgenya Shrainer iD, Marina Ermolaeva, Dmitry Kudlay iD, Michael Johnson, Richard Miller

Nutrients · 2024

DOI: 10.3390/nu16111550 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Nutrients, 2024. Verfasst von Evgeny Pokushalov und 9 weiteren Autor:innen. Beteiligte Einrichtung: Center for New Medical Technologies, 630090 Novosibirsk, Russia. Hauptthemen laut MEDLINE: Homocysteine, Dietary Supplements, Methylenetetrahydrofolate Reductase (NADPH2), 5-Methyltetrahydrofolate-Homocysteine S-Methyltransferase. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: S.Lab (SOLOWAYS).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Exploring the link between genetic polymorphisms in folate metabolism genes (MTHFR, MTR, and MTRR) and cardiovascular disease (CVD), this study evaluates the effect of B vitamin supplements (methylfolate, pyridoxal-5′-phosphate, and methylcobalamin) on homocysteine and lipid levels, potentially guiding personalized CVD risk management. In a randomized, double-blind, placebo-controlled trial, 54 patients aged 40–75 with elevated homocysteine and moderate LDL-C levels were divided based on MTHFR, MTR, and MTRR genetic polymorphisms. Over six months, they received either a combination of methylfolate, P5P, and methylcobalamin, or a placebo. At the 6 months follow-up, the treatment group demonstrated a significant reduction in homocysteine levels by 30.0% (95% CI: −39.7% to −20.3%) and LDL-C by 7.5% (95% CI: −10.3% to −4.7%), compared to the placebo (p < 0.01 for all). In the subgroup analysis, Homozygous Minor Allele Carriers showed a more significant reduction in homocysteine levels (48.3%, 95% CI: −62.3% to −34.3%, p < 0.01) compared to mixed allele carriers (18.6%, 95% CI: −25.6% to −11.6%, p < 0.01), with a notable intergroup difference (29.7%, 95% CI: −50.7% to −8.7%, p < 0.01). LDL-C levels decreased by 11.8% in homozygous carriers (95% CI: −15.8% to −7.8%, p < 0.01) and 4.8% in mixed allele carriers (95% CI: −6.8% to −2.8%, p < 0.01), with a significant between-group difference (7.0%, 95% CI: −13.0% to −1.0%, p < 0.01). Methylfolate, P5P, and methylcobalamin supplementation tailored to genetic profiles effectively reduced homocysteine and LDL-C levels in patients with specific MTHFR, MTR, and MTRR polymorphisms, particularly with homozygous minor allele polymorphisms.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HomocysteineDietary SupplementsMethylenetetrahydrofolate Reductase (NADPH2)5-Methyltetrahydrofolate-Homocysteine S-MethyltransferaseCholesterol, LDLVitamin B 12Pyridoxal PhosphateFerredoxin-NADP ReductaseTetrahydrofolatesHumansMiddle AgedFemaleMaleDouble-Blind MethodAgedAdultPolymorphism, GeneticVitamin B Complex

Stichwörter der Autor:innen

LDL-CMTHFRMTRMTRR polymorphismscardiovascular healthhomocysteinemethylcobalaminmethylfolatepersonalized medicinepyridoxal-5′-phosphatetriglycerides

Substanzen

HomocysteineMethylenetetrahydrofolate Reductase (NADPH2)5-Methyltetrahydrofolate-Homocysteine S-MethyltransferaseCholesterol, LDLmethionine synthase reductaseVitamin B 12Pyridoxal PhosphateFerredoxin-NADP ReductaseTetrahydrofolatesmecobalamin

Autor:innen und Institutionen

  • Center for New Medical Technologies, 630090 Novosibirsk, Russia.
  • Scientific Research Laboratory, Triangel Scientific, San Francisco, CA 94101, USA.
  • Institute of Pharmacy, I.M. Sechenov First Moscow State Medical University (Sechenov University), 119435 Moscow, Russia.

ORCID-Profile: Evgeny Pokushalov, Andrey Ponomarenko, Evgenya Shrainer, Dmitry Kudlay

Förderung

  • S.Lab (SOLOWAYS)

Zitieren

APA

Pokushalov, E., Ponomarenko, A., Bayramova, S., Garcia, C., Pak, I., Shrainer, E., Ermolaeva, M., Kudlay, D., Johnson, M., & Miller, R. (2024). Effect of Methylfolate, Pyridoxal-5′-Phosphate, and Methylcobalamin (SolowaysTM) Supplementation on Homocysteine and Low-Density Lipoprotein Cholesterol Levels in Patients with Methylenetetrahydrofolate Reductase, Methionine Synthase, and Methionine Synthase Reductase Polymorphisms: A Randomized Controlled Trial. Nutrients. https://doi.org/10.3390/nu16111550

Vancouver

Pokushalov E, Ponomarenko A, Bayramova S, Garcia C, Pak I, Shrainer E, et al. Effect of Methylfolate, Pyridoxal-5′-Phosphate, and Methylcobalamin (SolowaysTM) Supplementation on Homocysteine and Low-Density Lipoprotein Cholesterol Levels in Patients with Methylenetetrahydrofolate Reductase, Methionine Synthase, and Methionine Synthase Reductase Polymorphisms: A Randomized Controlled Trial. Nutrients. 2024. doi:10.3390/nu16111550

BibTeX
@article{Pokushalov2024,
  author = {Pokushalov, Evgeny and Ponomarenko, Andrey and Bayramova, Sevda and Garcia, Claire and Pak, Inessa and Shrainer, Evgenya and Ermolaeva, Marina and Kudlay, Dmitry and Johnson, Michael and Miller, Richard},
  title = {Effect of Methylfolate, Pyridoxal-5′-Phosphate, and Methylcobalamin (SolowaysTM) Supplementation on Homocysteine and Low-Density Lipoprotein Cholesterol Levels in Patients with Methylenetetrahydrofolate Reductase, Methionine Synthase, and Methionine Synthase Reductase Polymorphisms: A Randomized Controlled Trial},
  journal = {Nutrients},
  year = {2024},
  doi = {10.3390/nu16111550}
}
Kostenlos starten →